Winning Stock Forecast: Omeros Corporation Stock (NASDAQ: OMER) Revitalizes Your Portfolio With 70.31% In 14 Days

Winning Stock Forecast

“We believe that we now have clear paths to accelerated approval for OMS721 in both stem-cell TMA and IgA nephropathy. With breakthrough therapy designations in both of these indications, we look forward to continuing to work closely with FDA and, for stem-cell TMA, we have initiated preparations for a BLA submission”

– Gregory A. Demopulos, M.D., Chairman and CEO of Omeros

Over the 14 days period from May 1st to May 15th, 2018 OMER stock price experienced steep price rise of more than 70%. Taking into account the overall OMER stock performance indicators for the last quarter, it

Read More